Viridian Therapeutics Inc.
VRDN | NASDAQ
$22.05
+$0.47 (+2.18%)
Sep 22, 2026, 2:20 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 71.13M | 70.92M | 70.85M | 70.79M | 305K | 302K | 302K | 302K | 288K | 288K | 314K | 347K | 1.47M | 1.65M | 1.77M | 1.88M | 894K | 1.73M | 2.96M | 2.8M | 2.6M | 1.67M |
Cost of Revenue | 441K | 441K | 320K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 39.32M | 61.44M | 83.15M | 100.89M | 83.97M | 69.97M | 60.83M | 56.89M | 49.75M | 41.63M | 29.06M |
Gross Profit | 70.69M | 70.48M | 70.53M | 70.79M | 305K | 302K | 302K | 302K | 288K | 288K | 314K | -38.97M | -59.97M | -81.49M | -99.12M | -82.09M | -69.08M | -59.1M | -53.92M | -46.94M | -39.03M | -27.39M |
Operating Income | -405.2M | -385.7M | -363.4M | -328.12M | -371.59M | -337.01M | -299.04M | -283.04M | -250.79M | -237.87M | -254.45M | -232.04M | -210.6M | -180.89M | -134.3M | -114.32M | -98.67M | -87.1M | -79.73M | -141.25M | -132.52M | -120.9M |
Interest Income | 29.68M | 27.73M | 27.4M | 28.21M | 30.49M | 31.73M | 32.13M | 29.06M | 25.43M | 22.02M | 18.56M | 16.48M | 13.36M | 9.21M | 4.92M | 1.61M | 652K | 459K | 318K | 216K | 134K | 133K |
Pretax Income | -386.97M | -360.59M | -342.6M | -301.97M | -344.06M | -308.32M | -269.95M | -257.08M | -228.06M | -218.13M | -237.73M | -216.66M | -197.9M | -172.33M | -129.87M | -113.04M | -98.17M | -86.65M | -79.41M | -141.21M | -132.66M | -121.13M |
Net Income | -386.97M | -360.59M | -342.6M | -301.97M | -344.06M | -308.32M | -269.95M | -257.08M | -228.06M | -218.13M | -237.73M | -216.66M | -197.9M | -172.33M | -129.87M | -113.04M | -98.17M | -86.65M | -79.41M | -141.21M | -132.66M | -121.13M |
Selling & General & Admin | 151.65M | 116.89M | 95.32M | 77.23M | 67.31M | 63.16M | 61.08M | 78.49M | 85M | 88.19M | 95M | 71.86M | 59.81M | 48.65M | 35.18M | 32.23M | 29.59M | 28M | 25.81M | 24.44M | 20.52M | 16.7M |
Research & Development | 324.68M | 339.73M | 338.93M | 321.68M | 304.58M | 274.15M | 238.26M | 204.85M | 166.08M | 149.97M | 159.77M | 160.53M | 152.26M | 133.89M | 100.89M | 83.97M | 69.97M | 60.83M | 56.89M | 49.75M | 44.74M | 36.01M |
Other Expenses | -320K | -320K | -320K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -39.32M | -61.44M | -83.15M | -100.89M | -83.97M | -69.97M | -60.83M | -56.89M | 20.12M | 28.24M | 40.8M |
Operating Expenses | 475.89M | 456.18M | 433.92M | 398.91M | 371.89M | 337.31M | 299.34M | 283.34M | 251.07M | 238.16M | 254.76M | 193.07M | 150.63M | 99.39M | 35.18M | 32.23M | 29.59M | 28M | 25.81M | 94.3M | 93.49M | 93.51M |
Interest Expense | 18.94M | 11.14M | 8.27M | 2.52M | 2.96M | 3.05M | 3.05M | 3.1M | 2.7M | 2.27M | 1.85M | 1.1M | 663K | 651K | 486K | 321K | 157K | 3K | 3K | 180K | 273K | 367K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 476.33M | 456.62M | 434.24M | 398.91M | 371.89M | 337.31M | 299.34M | 283.34M | 251.07M | 238.16M | 254.76M | 232.39M | 212.07M | 182.54M | 136.08M | 116.2M | 99.56M | 88.83M | 82.69M | 144.05M | 135.12M | 122.57M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 107.88M | 102.21M | 84.8M | 81.78M | 81.59M | 81.34M | 80.05M | 66.42M | 63.85M | 61.1M | 49.68M | 43.65M | 43.25M | 42.24M | 40.54M | 33.74M | 27.76M | 26.13M | 11.18M | 11.18M | 8.11M | 6.34M |
Shares Outstanding (Diluted) | 107.88M | 102.21M | 84.8M | 81.78M | 81.59M | 81.34M | 80.05M | 66.42M | 63.85M | 61.1M | 49.68M | 43.65M | 43.25M | 42.24M | 40.54M | 33.74M | 27.76M | 26.13M | 11.18M | 11.18M | 8.11M | 6.34M |
EPS (Basic) | -3.53 | -3.71 | -3.55 | -3.25 | -4.06 | -3.85 | -3.77 | -4.31 | -4.25 | -4.50 | -5.32 | -5.02 | -4.76 | -4.55 | -3.92 | -5.46 | -5.89 | -7.05 | -8.98 | -29.46 | -29.68 | -29.28 |
EPS (Diluted) | -3.53 | -3.71 | -3.55 | -3.25 | -4.06 | -3.85 | -3.77 | -4.31 | -4.25 | -4.50 | -5.32 | -5.02 | -4.76 | -4.55 | -3.92 | -5.46 | -5.89 | -7.05 | -8.98 | -29.46 | -29.68 | -29.28 |
EBITDA | -368.03M | -349.44M | -334.33M | -298.99M | -340.62M | -304.76M | -266.36M | -253.41M | -224.78M | -215.29M | -235.37M | -215.09M | -196.85M | -171.36M | -129.13M | -112.52M | -97.86M | -86.52M | -79.35M | -71.12M | -62.45M | -50.79M |
EBIT | -368.04M | -349.45M | -334.33M | -299.45M | -341.1M | -305.27M | -266.9M | -253.98M | -225.36M | -215.86M | -235.89M | -215.56M | -197.24M | -171.68M | -129.39M | -112.71M | -98.02M | -86.64M | -79.47M | -71.26M | -62.62M | -50.99M |
Depreciation & Amortization | 8K | 4K | n/a | 463K | 483K | 512K | 540K | 567K | 572K | 562K | 522K | 468K | 395K | 320K | 255K | 191K | 159K | 127K | 120K | 138K | 165K | 204K |
Add to Watchlist
Select watchlists to add or remove VRDN